Tenaya Therapeutics Unveils Promising MyPeak™-1 Trial Data for TN-201
Tenaya Therapeutics announced interim Phase 1b/2 clinical trial data for TN-201, a gene therapy for •MYBPC3•-associated hypertrophic cardiomyopathy (HCM)....
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Tenaya Therapeutics announced interim Phase 1b/2 clinical trial data for TN-201, a gene therapy for •MYBPC3•-associated hypertrophic cardiomyopathy (HCM)....
JenaValve Technology announced positive results from an expanded 500-patient cohort in the ALIGN-AR Pivotal Trial, evaluating the Trilogy Transcatheter...
NeOnc Technologies Holdings, Inc. has received Rare Pediatric Disease Designation (RPDD) from the FDA for its perillyl alcohol (NEO100™)...
CorVista Health presented preliminary data at the American College of Cardiology’s Annual Scientific Session (ACC.25) demonstrating the potential of...
Treace Medical Concepts announced positive interim data from three clinical studies of its bunion and midfoot correction surgical procedures...
Tremfya (guselkumab), Johnson & Johnson’s IL-23 inhibitor, has received FDA approval for Crohn’s diseaseCrohn’s disease, adding to the existing...
Silexion Therapeutics Corp. (NASDAQ: SLXN) is expanding the development plan for its next-generation siRNA candidate, SIL204, to treat KRAS-driven...
Corbus Pharmaceuticals has dosed the first subject in a Phase 1 trial for CRB-913, an investigational drug for obesity....
FibroGen announced positive results from a Phase 1 study of FG-3246, an antibody-drug conjugate targeting CD46, in patients with...
Anthos Therapeutics presented new analyses from the AZALEA-TIMI 71 study at the American College of Cardiology Annual Scientific Session....